Advances in the study of anti-atherosclerosis drugs.
- Author:
Chang-Bin GUO
1
;
Song LI
Author Information
1. Institute of Pharmacology & Toxicology, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Apolipoprotein A-I;
therapeutic use;
Atherosclerosis;
drug therapy;
metabolism;
Benzoates;
chemistry;
therapeutic use;
Benzylamines;
chemistry;
therapeutic use;
Cholesterol Ester Transfer Proteins;
antagonists & inhibitors;
metabolism;
DNA-Binding Proteins;
agonists;
metabolism;
Humans;
Liver X Receptors;
Molecular Structure;
Orphan Nuclear Receptors;
Oxazines;
chemistry;
therapeutic use;
Peroxisome Proliferator-Activated Receptors;
agonists;
metabolism;
Phenylpropionates;
chemistry;
therapeutic use;
Quinolines;
chemistry;
therapeutic use;
Receptors, Cytoplasmic and Nuclear;
agonists;
metabolism
- From:
Acta Pharmaceutica Sinica
2007;42(3):231-235
- CountryChina
- Language:Chinese
-
Abstract:
Several new drug targets of anti-atherosclerosis, emerging in the recent years, such as PPAR agonists, cholesteryl ester transfer protein (CETP) inhibitors, infusion of apolipoprotein A-I (apoA-I), liver X receptor (LXR) activators and phospholipid transfer protein (PLTP) inhibitors etc were reviewed.
